PFE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Pfizer Inc is not a strong buy for a beginner investor with a long-term strategy at this moment. The company's financial performance is weak, with significant declines in revenue, net income, and EPS. Analysts have a predominantly negative outlook, citing structural headwinds and revenue uncertainties. While the stock offers a high dividend yield, it does not offset the lack of near-term growth catalysts. Technical indicators are mixed, and there are no strong proprietary trading signals or recent influential trades to suggest immediate upside potential. Therefore, holding off on investing in Pfizer is recommended for now.
The technical indicators are mixed. The MACD is negatively expanding, indicating bearish momentum. RSI is neutral at 51.754, suggesting no clear signal. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading near its pivot point of 27.155, with resistance at 27.76 and support at 26.549.
The stock has a high dividend yield of 6%, which provides some downside support. Gross margin increased by 6% YoY in Q4 2025.
Analysts highlight significant revenue cliffs of $15B-$20B through 2030, with no visible near-term pipeline to offset losses. Financial performance in Q4 2025 was poor, with revenue down 1.16% YoY, net income down 501.95% YoY, and EPS down 514.29% YoY. Analysts have issued predominantly negative ratings and price targets, with most targets around or below the current price. The MACD indicates bearish momentum.
In Q4 2025, revenue dropped by 1.16% YoY to $17.557 billion. Net income plunged by 501.95% YoY to -$1.648 billion, and EPS dropped by 514.29% YoY to -$0.29. Gross margin improved to 64.15%, up 6% YoY.
Analysts are predominantly bearish. RBC Capital and Barclays initiated coverage with Underperform/Underweight ratings and a $25 price target, citing revenue cliffs and lack of catalysts. Cantor Fitzgerald and UBS maintain Neutral ratings with price targets of $27 and $25, respectively. HSBC is the only firm with a Buy rating and a $29 price target, citing potential sector outperformance.
